|
Fighting The War Against
Deadly Diseases
by Glenn Wilkins - AllPennyStocks.com News Reporter
June 13, 2005 (AllPennyStocks.com Media, Inc.) - Perhaps it
dates back to the days when diseases and the means to cure
them were all in Latin, but some words that mean the most to
our health and well-being are very hard to spell or pronounce.
So it is with Chemokine Therapeutics (CTI
:TSX), a company developing synthetic chemokines
(pronounced KEE-MO-KINES) to address diseases, which threaten
us all.
Beginning life in the summer of 1998 in the state of
Delaware, Chemokine conducts much of its business through its
subsidiary, Chemokine Therapeutics (B.C.) Corporation, located
on the Vancouver campus of the University of British Columbia,
with offices in New York City as well. Chemokine develops
therapies to treat cancer, cardiovascular and infectious
disease, efforts which bore fruit this spring with strong
results from tests of its anti-cancer compound. Phase One
clinical trials appeared to confirm the safety and efficacy of
CTCE-0214 for stimulating rapid mobilization and regeneration
of infection-fighting white and other blood cells. This drug
could potentially restore a cancer patient's immune system and
blood cells between cycles of chemotherapy, thus it's a
breakthrough for cancer treatment if successful.
And news of the Company's drugs for cancer and immune
recovery is finding receptive ears; such reputable facilities
as the National Cancer Institute, Memorial Sloan Kettering
Institute in New York and Indiana's Walther Cancer Institute
have been collaborating with and publishing their research
with Chemokine's new developments. A study conducted by NCI
demonstrated that the Company's CTCE-9908 decreased the spread
of lung cancer in mice by 67%, results made known at the
annual American Association for Cancer Research (AACR) meeting
in April.
In the U.S. alone, the pharmaceuticals market is growing by
leaps and bounds. According to the IMS Health World Review for
2004, audited pharmaceutical sales grew at a 9% rate to $466.3
billion (all figures in U.S. dollars unless specified
otherwise) in 2003. Worldwide sales of medications to treat
low white blood cell counts in cancer and immune disorders
were $3 billion in 2003, a figure projected to increase to
about $4.5 billion by 2008. The Company hopes the specialized
treatments it's developing could garner it at least a small
piece of this increasingly bigger pie, a piece lucrative
enough to make Chemokine worth an investor's while.
Even so, research and development costs totaled $1.7
million during 2004 (only slightly less than the year before),
contributing to a net loss of $3.1 million on the year.
Chemokine found itself, however, with a cash reserve of $11.1
million at the end of last year, having closed an initial
public offering of 16-million shares at $1.00 per share
(Canadian), proceeds added to early in New Year 2005 with an
additional $1.9 million following the closing of an
over-allotment or "greenshoe" option. Its research
collaboration in cardiovascular drugs with Procter & Gamble's
pharmaceutical arm is expected to inject another $275,000 into
Chemokine's coffers, besides the prestige resulting from a
hook-up with a company with vast resources such as P&G.
The stock trades on the Toronto Stock Exchange under the
symbol CTI, and the Company is impatient for the price to move
off its original $1.00 Canadian. But the fact that the price
remains in that range - quite a ways off March's 52-week peak
of $1.50 Canadian - should attract investors in search of a
growing company that has developed new technology with social
as well as economic import.
The Company hails this technology as breakthrough stuff,
which may prove useful in the very near future in the war
against infectious diseases and cancer. But concentrating on
this important research entails big capital inflows from
small-cap investors, willing and able to share some of the
risk of that research with the company. Chemokine is on its
way, and hopes to take on more passengers as it treats what
ails some of us.
Copyright © 2007 AllPennyStocks.com. All
rights reserved. Republication or redistribution of
AllPennyStocks.com's content is expressly prohibited without
the prior written consent of AllPennyStocks.com.
AllPennyStocks.com shall not be liable for any errors or
delays in the content, or for any actions taken in reliance
thereon.
|
